ALS Biopharma receives ADDF grant to build up therapeutics against Alzheimer’s disease The Alzheimer’s Medication Discovery Base announced today that it has awarded a grant of $195,000 to ALS Biopharma, LLC to build up therapeutics targeted at clearing toxic proteins implicated in Alzheimer’s disease.The program will identify and develop small-molecule brain-penetrant inducers of heat shock protein 70 . Allen Reitz, CEO of ALS Biopharma. ‘We are excited to aid ALS Biopharma’s innovative plan in this target area,’ said Howard Fillit, MD, Executive Director of the ADDF.’.Related StoriesUltrasonic attenuation could be early indicator of preterm-birth riskStudy raises possibility of using ultrasound ways to detect symptoms of preterm laborUsing integrated molecular pathology to control incidental pancreatic cysts: an interview with Dr Ananya DasAbstract submissions THE BUILDING BLOCKS welcomes abstracts linked to preclinical, scientific or translational research that involves the usage of MR-guided focused ultrasound. Topics of interest include, but aren’t limited to, emerging remedies for the brain, prostate, breast, uterus and liver and for bone tumors, back and neck discomfort and targeted drug delivery.
000 to ALS Biopharma.
Warning: Division by zero in /home/amandabrayman/public_html/wp-includes/comment-template.php on line 1379